Actinogen Medical has obtained positive scientific advice from the European Medicines Agency that aligns with prior FDA guidance, clarifying regulatory requirements for its Alzheimer’s drug Xanamem and paving the way for a streamlined approval process in major markets.
- EMA agrees on regulatory starting materials for Xanamem
- One additional pivotal Phase 3 trial planned with broader patient inclusion
- EMA and FDA guidance align on safety database and ancillary studies
- Final XanaMIA trial results expected November 2026
- Second pivotal trial to commence mid-2027
EMA Confirms Streamlined Approval Pathway
Actinogen Medical (ASX:ACW) has received encouraging scientific advice from the European Medicines Agency (EMA) that closely mirrors earlier guidance from the US Food and Drug Administration (FDA), providing a clearer regulatory roadmap for its Alzheimer’s drug Xanamem (emestedastat). This alignment significantly de-risks the company’s development program by specifying the manufacturing standards, clinical trial design, and ancillary studies required for marketing approval in Europe.
The EMA confirmed the suitability of the regulatory starting materials used in the commercial manufacture of Xanamem, a critical step in ensuring drug quality and consistency. Furthermore, the agency agreed that only one additional well-controlled pivotal Phase 3 trial, using a 10 mg dose of Xanamem versus placebo, will be necessary following the ongoing XanaMIA trial. This trial design also includes a broader inclusion criterion to encompass patients with moderate Alzheimer’s disease, potentially expanding the drug’s target population.
Regulatory Clarity Supports Global Strategy
Actinogen’s CEO Dr Steven Gourlay highlighted the importance of this regulatory clarity, stating that the EMA’s agreement on a single pivotal trial aligns with the company’s streamlined development plans. This consensus between the EMA and FDA not only simplifies the approval process in the two largest pharmaceutical markets but also facilitates subsequent approvals in other regions.
The EMA’s advice also outlines the expected safety database size consistent with FDA guidelines, alongside a small number of ancillary clinical pharmacology and nonclinical studies to further characterise Xanamem’s safety, metabolism, and excretion. These requirements set clear parameters for Actinogen’s ongoing regulatory discussions and potential partnerships.
Clinical Milestones on the Horizon
The company anticipates releasing topline results from its pivotal XanaMIA Phase 2b/3 trial in November 2026. This trial, which enrolled 247 patients with mild to moderate Alzheimer’s disease confirmed by a blood biomarker, is testing the efficacy of Xanamem 10 mg once daily against placebo in slowing disease progression. The trial has already passed an independent Data Monitoring Committee review, reinforcing confidence in its continuation and safety profile, as detailed in prior coverage of the positive XanaMIA interim analysis.
Following these results, Actinogen plans to initiate a second pivotal trial in mid-2027 with broader patient inclusion criteria, potentially capturing a wider segment of the Alzheimer’s population. Meanwhile, the open-label extension phase of XanaMIA, offering all participants active Xanamem treatment for up to 25 months, is ongoing and aims to provide additional long-term safety and efficacy data, as reported in the open-label phase extension.
Xanamem’s Novel Mechanism and Development Progress
Xanamem targets elevated brain cortisol levels by inhibiting the enzyme 11β-HSD1, a novel approach designed to protect brain cells and slow cognitive decline without disrupting essential cortisol production elsewhere in the body. Actinogen has tested Xanamem in over 500 volunteers and patients across eight clinical trials, demonstrating a promising safety profile and clinical activity in both Alzheimer’s and depression cohorts.
The recent positive outcomes from the XanaCIDD depression trial further validate the cortisol control mechanism, showing significant improvements in depressive symptoms. This reinforces the potential of Xanamem as a first-in-class therapy addressing neurological diseases linked to dysregulated brain cortisol.
Bottom Line?
With EMA and FDA alignment, Actinogen’s Alzheimer’s program advances into a critical phase ahead of key trial results and expanded clinical plans.
Questions in the middle?
- Will the November XanaMIA results confirm Xanamem’s efficacy to support marketing approval?
- How will broader inclusion criteria in the next pivotal trial affect patient outcomes and regulatory acceptance?
- What partnerships or licensing deals might emerge following regulatory clarity from EMA and FDA?